Press Releases Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
3.92 ^USD	+1.29%		-10.71%	-39.13%

May. 23	Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	MT
May. 21	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates	May. 17	GL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress	May. 14	GL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress	May. 14	AQ
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call	May. 13	GL
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call	May. 13	AQ
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO	Apr. 24	GL
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	Apr. 23	GL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	Apr. 02	GL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	Apr. 02	AQ
Autolus Therapeutics Announces Changes to its Board of Directors	Apr. 01	GL
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates	Mar. 14	GL
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates	Mar. 14	AQ
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site	Mar. 12	GL
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site	Mar. 12	AQ
Autolus Therapeutics announces publication in Blood Cancer Journal	Mar. 11	GL
Autolus Therapeutics announces publication in Blood Cancer Journal	Mar. 11	AQ
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024	Feb. 29	GL
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024	Feb. 29	AQ
Autolus Therapeutics announces publication in Nature Communications	Feb. 22	GL
Autolus Therapeutics announces publication in Nature Communications	Feb. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Press Releases

Filters